Advanced Filters
noise

Birth Defects Clinical Trials

A listing of Birth Defects medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 299 clinical trials
H Holly L Hedrick, MD

Safety and Efficacy of FETO in CDH: A Phase III Trial

Congenital diaphragmatic hernia (CDH) is a birth defect characterized by the development of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs …

18 years of age Female Phase N/A
G Grazia Chiara Menozzi

Advanced Surgical Simulation Processes in the Correction of Skeletal Defects and Deformities

Virtual Surgical Planning (VSP), Computer-Aided Surgical Simulation (CASS) for bone corrections, and the customization of implants and devices through 3D printing, known as Patient-Specific Instruments (PSI) and Graft-Specific Instruments (GSI), are assuming increasingly central roles in orthopedic clinical and surgical practice. One area witnessing notable advancement is the treatment of …

2 - 40 years of age All Phase N/A
J Jose L Peiro, MD, PhD, MBA

Feto-Endoscopic Tracheal Occlusion (FETO) for Left Congenital Diaphragmatic Hernia

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.

18 - 50 years of age Female Phase N/A
E Erin Watters, BA

Safety and Efficacy of FETO in CDH Phase III

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses and standard of care control group

18 - 50 years of age Female Phase 3
S Stephen Luen, MBBS

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 48 weeks of alpelisib …

2 years of age All Phase 2
A Ahmet A Baschat, MD

Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDH

The purpose of this study is to evaluate successful placement and removal of Fetoscopic Endoluminal Tracheal Occlusion (FETO) device in cases of intrathoracic liver herniation with isolated left congenital diaphragmatic hernia (LCDH) with Observed/Expected (O/E) Lung to Head Circumference Ratio (LHR) < 30% or isolated right congenital diaphragmatic hernia (RCDH) …

18 years of age Female Phase N/A
J Jean Michel DUPONT, Dr

Prospective Study to Assess Medical Performance of Optical Mapping and Long Read Sequencing in Detecting Numerical and Structural Chromosome Abnormalities

Chromosomal aberrations are major causes of developmental disorders (Intellectual disability (ID), multiple congenital anomalies (MCA), autism spectrum disorders (ASD)) as well as reproductive disorders (RD) in particular gametogenesis defects and recurrent miscarriages. Current first tier genetic investigations for chromosome analysis in clinical settings include karyotyping in case of RD (5 …

years of age All Phase N/A
F Fabien Chaillot

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the venous/lymphatic vascular organisations. The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.

3 - 70 years of age All Phase 3
J Jian Ren, MD

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

This study is a single-arm exploratory trial conducted by Xuanwu Hospital, Capital Medical University, aiming to evaluate the efficacy and safety of everolimus monotherapy in adult patients with vascular malformations.

18 - 65 years of age All Phase 2

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

Among people living with HIV, heavy drinking increases the risk of heart disease and death. Studies suggest that alcohol changes the number and kind of bacteria in your gut and these changes increase the risk of heart disease and death. This randomized controlled trial will determine whether a pill containing …

18 - 89 years of age All Phase 2

Simplify language using AI